Endpoints News

China biotech to test mRNA therapy for gout in US		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M Tue W Th F

17 March, 2026

AI-driven drug discovery is already reshaping pipelines. But algorithms alone won’t get a drug to the clinic. Join us for a free virtual program — then continue the conversation at an in-person only fireside chat and happy hour in Boston. Reserve your spot.

presented by

5 ways to secure biotech funding in 2026

news

J&J pulls out of JLABS New York location as it shrinks incubator footprint

Exclusive: China mRNA therapy startup Innorna to test gout treatment in US

New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2b

Updated: Federal judge halts CDC’s childhood vaccine overhaul

Mar 24

11:30 am ET

From structure to selectivity: Federated AI for collaborative binding affinity prediction

in case you missed it

Exclusive: China startup CirCode gets clearance for trial of circular RNA therapy

Makary pushes for IRB reforms to catch China's speedy trial starts

BioMarin halts Phase 2 Voxzogo dosing in certain patients over safety concern

Structure Therapeutics reports more Phase 2 data for oral GLP-1

News Briefing

CytomX reports ADC data in late-line colorectal cancer; FDA OKs Cosentyx label expansion

Unnatural Products gets $45M to test decadelong work on macrocyclic peptides

Former MD Anderson researcher in Houston gets jail time after attempt to smuggle data to China

Houston Chronicle

China Clamps Down on Key Route to Hong Kong IPOs After Deal Boom

China pledges billion-dollar spending boost for science

You might be wondering why Innorna is investigating the use of its mRNA therapy for gout. But as Ryan Cross explains here, the implications of the Chinese biotech's findings can go beyond this type of inflammatory arthritis.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com